Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLEUPROLIDE ACETATE (leuprolide acetate) by Novartis is clinical pharmacology leuprolide acetate, a gnrh agonist, acts as an inhibitor of gonadotropin secretion. Approved for the palliative treatment of advanced prostatic cancer. First approved in 1998.
Drug data last refreshed 18h ago
CLINICAL PHARMACOLOGY Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was…
Worked on LEUPROLIDE ACETATE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo